Spark Therapeutics Reports Positive Phase 3 Results In Patients With Rare Blindness
October 05, 2015 at 19:54 PM EDT
Shares of Spark Therapeutics ended the day up 25% after reporting positive phase 3 results for its SPK-RPE65 gene therapy.
